5d 1m 3m 1y 5y 10y
There are no Related articles on IMMY.
There are no Transcripts on IMMY.
PR Newswire (Mar 4, 2014)
IMMY vs. ETF Alternatives
Friday, Dec 132013, 12:51 PM|Friday, Dec 132013, 12:51 PM| 3 Comments
Wednesday, Aug 282013, 1:57 PMImprimis Pharmaceuticals acquires the intellectual property rights for ophthalmic compound from Novel Drug Solutions
Wednesday, Aug 282013, 1:57 PM| Comment!
- Imprimis Pharmaceuticals (IMMY -4.7%) acquires the intellectual property, including a provisional patent application, related to an ophthalmic compound for intraoperative ocular injection of anti-inflammatory and anti-bacterial agents from Novel Drug Solutions.
- The target compound, referred to as IPI-140, is based on a combination of moxifloxacin and triamcinolone.
- IMMY says it believes the formulation has the potential to "impact the fast-growing $5B global cataract surgery drug market."
- Additionally, the deal gives IMMY preemptive rights to other Novel Drug Solutions and Eye Care Northwest intellectual property and drug development opportunities.
Tuesday, Aug 132013, 12:45 PM|Tuesday, Aug 132013, 12:45 PM| Comment!
Monday, Jul 152013, 12:45 PM
Thursday, Apr 182013, 2:31 PMImprimis Pharmaceuticals (IMMY +12%) ramps higher today after the company says that had concluded its Type C meeting with the FDA, which included the review of the development plan for its lead phase 3 drug candidate, Impracor, a topical cream Non-Steroidal Anti-Inflammatory Drug. |Thursday, Apr 182013, 2:31 PM| Comment!
We currently have no instablog posts on this stock.
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.